Yahr M - Search Results

1

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.

Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M. Lieberman A, et al. Among authors: yahr m. Neurology. 1998 Oct;51(4):1057-62. doi: 10.1212/wnl.51.4.1057. Neurology. 1998. PMID: 9781529 Clinical Trial.

2

Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.

Bhattacharya KF, Nouri S, Olanow CW, Yahr MD, Kaufmann H. Bhattacharya KF, et al. Among authors: yahr md. Parkinsonism Relat Disord. 2003 Mar;9(4):221-4. doi: 10.1016/s1353-8020(02)00053-6. Parkinsonism Relat Disord. 2003. PMID: 12618057 Clinical Trial.

3

Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.

Brannan T, Yahr MD. Brannan T, et al. Among authors: yahr md. Ann Neurol. 1995 Jan;37(1):95-8. doi: 10.1002/ana.410370117. Ann Neurol. 1995. PMID: 7818264 Clinical Trial.

4

Parkinson's disease. The L-dopa era.

Yahr MD. Yahr MD. Adv Neurol. 1993;60:11-7. Adv Neurol. 1993. PMID: 8420128 Review. No abstract available.

5

L-deprenyl, a MAO-B inhibitor, as an adjunct to conventional L-dopa therapy in Parkinson's disease: experience in 200 patients.

Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. Elizan TS, et al. Among authors: yahr md. Adv Neurol. 1990;53:431-5. Adv Neurol. 1990. PMID: 2122649 Clinical Trial. No abstract available.

6

Cholinergic and dopaminergic mechanisms in Parkinson's disease after long-term L-DOPA administration.

Clough CG, Bergmann KJ, Yahr MD. Clough CG, et al. Among authors: yahr md. Adv Neurol. 1984;40:131-40. Adv Neurol. 1984. PMID: 6695589

7

Parkinson's disease: progression and mortality in the L-DOPA era.

Di Rocco A, Molinari SP, Kollmeier B, Yahr MD. Di Rocco A, et al. Among authors: yahr md. Adv Neurol. 1996;69:3-11. Adv Neurol. 1996. PMID: 8615142 Clinical Trial. No abstract available.

8

Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.

Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. Elizan TS, et al. Among authors: yahr md. Arch Neurol. 1989 Dec;46(12):1280-3. doi: 10.1001/archneur.1989.00520480022013. Arch Neurol. 1989. PMID: 2511825 Clinical Trial.

9

Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months.

Elizan TS, Moros DA, Yahr MD. Elizan TS, et al. Among authors: yahr md. Arch Neurol. 1991 Jan;48(1):31-4. doi: 10.1001/archneur.1991.00530130039017. Arch Neurol. 1991. PMID: 1898848

10

Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.

Askenasy JJ, Yahr MD. Askenasy JJ, et al. Among authors: yahr md. Neurology. 1985 Apr;35(4):527-32. doi: 10.1212/wnl.35.4.527. Neurology. 1985. PMID: 3982638

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206 results

Search Page

Filters